The possibility of using pharmacological antiarrhythmic therapy and modulated kinesotherapy as a primary prevention of atrial fibrillation in patients with metabolic syndrome and with premature atrial complexes: prospective study

Highlights. The results of primary prevention of atrial fibrillation by using antiarrhythmic drug therapy and modulated kinesitherapy in patients with metabolic syndrome with premature atrial complexes are presented.

A significant decrease in the development of the disease was revealed in patients with metabolic syndrome and risk of atrial fibrillation within a year after the examination with the help of pharmacological antiarrhythmic therapy of atrial ectopia and modulated kinesotherapy as primary prevention in comparison with therapy aimed at correcting blood pressure, glucose and blood lipids.

Aim. To assess the possibility of using antiarrhythmic drug therapy (DT) and modulated kinesitherapy (MK)  in patients with metabolic syndrome (MS) and premature atrial complexes (PAC) as the primary prevention of atrial fibrillation (AF).

Methods. 426 MS patients with PAC aged from 58 to 72 years (mean 66.4±0.7 years) were included in the study. All patients had a high probability of developing primary AF within 1 year after the enrollment. Antiarrhythmic DT with class I–III  drugs was used as the primary prophylaxis of AF in 149 (34.97%) patients, MK  – in 121 (28.40%), the correction of blood pressure, glucose and blood lipids – in 156 (36.63%). All patients were followed up for one year and the end point of observation was the maintenance of sinus rhythm or AF registration.

Results. Various clinical forms of AF were recorded in 26.45, 31.54% and 95.51% of patients with MS during primary prevention with the help of pharmacological AAT, UA and correction of its potentially modifiable components (arterial pressure, glucose and blood lipids), respectively, during the year after the examination.

Conclusion. The use of both antiarrhythmic DT of I–III classes, and MК as a primary prophylaxis of AF in patients with MS with PAC and the risk of AF development within one year after the first examination made it possible to reduce the frequency of the arrhythmia by the correction of blood pressure, glucose and blood lipids.

1. Vyas V., Lambiase P. Obesity and Atrial Fibrillation: Epidemiology, Pathophysiology and Novel Therapeutic Opportunities. Arrhythm Electrophysiol Rev. 2019;8(1):28–36. doi:10.15420/aer.2018.76.2

2. Shamloo A.S., Dagres N., Arya A., Hindricks G. Atrial fibrillation: A review of modifiable risk factors and preventive strategies. Rom J Intern Med. 2019;57(2):99-109. doi: 10.2478/rjim-2018-0045.

3. Golub I.V. Physiological Mechanisms of the Effect of Modulated Kinesotherapy on the Circulatory System. Human Physiology. 2002:28(6):747–752. (In Russian) https://doi.org/10.1023/A:1021172927503

4. Olesin A.I., Litvinenko V.A., Konstantinova I.V., Shlapakova A.V. A possibility to use antiarrhythmic medication from II class and modulated kinesitherapy as primary prevention of atrial fibrillation in metabolic syndrome patients. Russian Journal of Cardiology. 2015;(11):75-80. (In Russian) http://dx.doi.org/10.15829/1560-4071-2015-11-75-80

5. Olesin A.I., Litvinenko V.A.,Al-Barbari A.V., Konstantinova I.V., Smolin Z. Yu., Prosyanikova O.N. Atrial fibrillation onset risk in patient with metabolic syndrome: prospective study. Russian Journal of Cardiology, 2014; 12 (116): 25–30. (In Russian) http://dx.doi.org/10.15829/1560-4071-2014-12-25-30

6. Olesin A.I., Konstantinova I.V., Litvinenko V.A., Al-Barbary A.V. Method for determine risk development of atrial fibrillation in patients with atrial exstrasystoles. Patent RU № 2556602, publ. 10.07.15, Bul. № 19. (In Russian) http://www.findpatent.ru/patent/255/2556602.html

7. Olesin A.I., Litvinenko V.A., Shlapakova A.V., Konstantinova I.V. Estimation of atrial fibrillation risk development in patients with metabolic syndrome during atrial extrasystole registration. International Heart and Vascular Disease Journal. 2016; 4(11): 17-27. (In Russian) http://dx.dоi/10.15829/2311-1623-4-11

8. Olesin A.I., Konstantinova I.V., Litvinenko V.A., Shlapakova A.V., Zueva Y.S. A method for predicting the effectiveness of pharmacological antiarrhythmic therapy as primary prevention of atrial fibrillation in patients with atrial extrasystole. Patent RU № 2688394, publ. 21.05.2019, Bul. № 15, (In Russian) http://www.findpatent.ru/patent/268/2688394.html

9. Olesin A.I., Konstantinova I.V., Litvinenko V.A., Shlapakova A.V. A method for predicting the effectiveness of modulated kinesitherapy as primary prevention of atrial fibrillation in patients with atrial extrasystole. Patent RU № 2667827, publ. 24.09.2018, Bul. № 27. (In Russian) http://www.findpatent.ru/patent/266/2667827.html

10. Varma N., Cyqankiewicz I., Terakhia M., Heidbuchel H., Hu Y., Chen L.Y., Couderc J.P., Cronin E.M., Estep J.D., Grieten L., Lane D.A., Mehra R., Page A., Passman R., Piccini J., Piotrowicz E., Piotrowicz R., Platonov P.G., Ribeiro A.L., Rich R.E., Russo A.M., Slotwiner D., Steinberg J.S., Svennberg E. 2021 ISHNE/HRS/EHRA/APHRS collaborative statement on mHealth in Arrhythmia Management: Digital Medical Tools for Heart Rhythm Professionals. From the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society. J Arrhythm. 2021;37(2): 271–319. doi: 10.1002/joa3.12461

11. Wu Y., Xie Z., Liang W., Xue R., Wu Z., Wu D., He J., Zhu W., Liu C. Usefulness of CHADS2, R2CHADS2, and CHA2DS2‐VASc scores for predicting incident atrial fibrillation in heart failure with preserved ejection fraction patients. ESC Heart Fail. 2021; 8(2): 1369–1377. doi: 10.1002/ehf2.13217

12. Boriani G., Palmisano P., Malavasi V.L., Fantecchi E., Vitolo M., Bonini N., Imberti J., Valenti A.C., Schnabel R.B., Freedman B. Clinical Factors Associated with Atrial Fibrillation Detection on Single-Time Point Screening Using a Hand-Held Single-Lead ECG Device. J Clin Med. 2021; 10(4): 729. doi: 10.3390/jcm10040729

13. Himmelrech J.C.L., Veeler L., Lucassen W.A.M., Schnabel R.B., Rienstra M., van Weert H.C.P.M., Harskamp R.E. Prediction models for atrial fibrillation applicable in the community: a systematic review and meta-analysis. Europace. 2020;22(5): 684–694. doi: 10.1093/europace/euaa005

14. Himmelrech J.C.L., Lucassen W.A.M., Harskamp R.E., Aussems C., van Weert H.C.P.M., Nielen M.M.J. CHARGE- AF in a national routine primary care electronic health records database in the Netherlands: validation for 5-year risk of atrial fibrillation and implications for patient selection in atrial fibrillation screening. Open Heart. 2021; 8(1): e001459. doi: 10.1136/openhrt-2020-001459

15. Bo B., Zhou Y., Zheng Q., Wang G., Zhou K., Wei J. The Molecular Mechanisms Associated with Aerobic Exercise-Induced Cardiac Regeneration. Biomolecules. 2021;11(1):19. doi: 10.3390/biom11010019.